Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
Alimentary Pharmacology & Therapeutics2016Vol. 45(2), pp. 276–282
Citations Over TimeTop 1% of 2016 papers
Bella Ungar, Uri Kopylov, Tal Engel, Miri Yavzori, Ella Fudim, Orit Picard, Anthony E. Lang, Nicolas Williet, Stéphane Paul, Yehuda Chowers, Ariella Bar‐Gil Shitrit, Rami Eliakim, Shomron Ben‐Horin, Xavier Roblin
Abstract
In almost half of inflammatory bowel disease patients developing anti-adalimumab antibodies and loss of response, established immunogenicity of adalimumab can be gradually reversed by the addition of immunomodulator therapy with restoration of a clinico-biological response. However, these observations need to be confirmed with larger studies.
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)